Literature DB >> 23549631

Unresponsive thrombotic thrombocytopenic purpura in critically ill adults.

Eric Mariotte1, Alice Blet, Lionel Galicier, Michael Darmon, Nathalie Parquet, Etienne Lengline, David Boutboul, Emmanuel Canet, Richard Traineau, Benoît Schlemmer, Agnès Veyradier, Elie Azoulay.   

Abstract

INTRODUCTION: The prognosis of thrombotic thrombocytopenic purpura (TTP) has considerably improved since the introduction of plasma exchange (PEX) therapy. However, unresponsive thrombotic thrombocytopenic purpura (Un-TTP) still carries high morbidity and mortality rates, indicating a need for early specific treatments. PATIENTS AND METHODS: In a retrospective study including consecutive adults with TTP admitted between January 1997 and January 2011 in a teaching hospital intensive care unit (ICU), our objective here is to identify early clinical and laboratory features predicting Un-TTP. Patients who responded to plasma exchange and steroids (N = 49) were compared with patients with unresponsive TTP defined as requirement for other treatments, protracted course, or death (N = 37, 43 %).
RESULTS: Hospital mortality was 24.3 % in the Un-TTP group. Variables associated with Un-TTP on univariate logistic regression were older age, cardiac involvement, neurological involvement, higher anti-a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS13) immunoglobulin G (IgG) titer, lower platelet counts starting on day 2, higher Sequential Organ Failure Assessment (SOFA) scores starting on day 3, need for higher plasma volumes to obtain remission, and greater use of adjuvant treatments and life-sustaining interventions. Multivariate logistic regression identified four factors independently associated with Un-TTP: age over 60 years [odds ratio (OR) 7.90; 95 % confidence interval (95 % CI) 1.06-78.34], cardiac (OR 5.17; 95 % CI 1.63-16.39) or neurological (OR 8.04; 95 % CI 1.27-51.03) manifestations at diagnosis, and day 2 platelet count less than 15 G/l (OR 3.88; 95 % CI 1.30-11.62).
CONCLUSION: Therapeutic intensification starting on day 3 or even earlier in patients with the independent risk factors for unresponsive TTP identified in our study deserves evaluation in a multicenter prospective study.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23549631     DOI: 10.1007/s00134-013-2873-4

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  37 in total

1.  Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias.

Authors:  Sarah L Allford; Beverley J Hunt; Peter Rose; Samuel J Machin
Journal:  Br J Haematol       Date:  2003-02       Impact factor: 6.998

2.  Long-term, sub-clinical cardiac and renal complications in patients with multiple relapses of thrombotic thrombocytopenic purpura.

Authors:  Srividya Viswanathan; Brad H Rovin; Ganesh B Shidham; Subha V Raman; Mitchell Weinberg; Allenby Patricia; James N George; Haifeng M Wu; Spero R Cataland
Journal:  Br J Haematol       Date:  2010-02-09       Impact factor: 6.998

3.  The Multiple Organ Dysfunction Score (MODS) versus the Sequential Organ Failure Assessment (SOFA) score in outcome prediction.

Authors:  Daliana Peres Bota; Christian Melot; Flavio Lopes Ferreira; Vinh Nguyen Ba; Jean-Louis Vincent
Journal:  Intensive Care Med       Date:  2002-09-06       Impact factor: 17.440

4.  Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; A Li; G Rock
Journal:  Clin Lab       Date:  2001       Impact factor: 1.138

5.  Time course of organ dysfunction in thrombotic microangiopathy patients receiving either plasma perfusion or plasma exchange.

Authors:  Michael Darmon; Elie Azoulay; Guillaume Thiery; Magali Ciroldi; Lionel Galicier; Nathalie Parquet; Agnès Veyradier; Jean-Roger Le Gall; Eric Oksenhendler; Benoît Schlemmer
Journal:  Crit Care Med       Date:  2006-08       Impact factor: 7.598

6.  Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura.

Authors:  Friedrich Scheiflinger; Paul Knöbl; Bettina Trattner; Barbara Plaimauer; Gabriele Mohr; Michael Dockal; Friedrich Dorner; Manfred Rieger
Journal:  Blood       Date:  2003-07-10       Impact factor: 22.113

7.  Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006.

Authors:  Loan Nguyen; Xiaoning Li; Deanna Duvall; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Transfusion       Date:  2007-11-19       Impact factor: 3.157

Review 8.  Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2008-07-01       Impact factor: 22.113

Review 9.  Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura.

Authors:  Karen K Swisher; Deirdra R Terrell; Sara K Vesely; Johanna A Kremer Hovinga; Bernhard Lämmle; James N George
Journal:  Transfusion       Date:  2009-02-06       Impact factor: 3.157

Review 10.  Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.

Authors:  Miha Furlan
Journal:  Expert Rev Cardiovasc Ther       Date:  2003-07
View more
  8 in total

1.  Does this patient with thrombotic thrombocytopenic purpura have a cardiac involvement?

Authors:  Lara Zafrani; Lene Russell; Elie Azoulay
Journal:  Intensive Care Med       Date:  2018-06-04       Impact factor: 17.440

2.  Year in review in Intensive Care Medicine 2013: II. Sedation, invasive and noninvasive ventilation, airways, ARDS, ECMO, family satisfaction, end-of-life care, organ donation, informed consent, safety, hematological issues in critically ill patients.

Authors:  Elie Azoulay; Giuseppe Citerio; Jan Bakker; Matteo Bassetti; Dominique Benoit; Maurizio Cecconi; J Randall Curtis; Glenn Hernandez; Margaret Herridge; Samir Jaber; Michael Joannidis; Laurent Papazian; Mark Peters; Pierre Singer; Martin Smith; Marcio Soares; Antoni Torres; Antoine Vieillard-Baron; Jean-François Timsit
Journal:  Intensive Care Med       Date:  2014-01-24       Impact factor: 17.440

3.  The clinical features of cardiac involvement in patients with severe thrombotic thrombocytopenic purpura.

Authors:  Aude-Marie Fourmont; Lara Zafrani; Eric Mariotte; Lionel Galicier; Bérangère Joly; Sybille Merceron; Rémi Bertinchamp; Virginie Lemiale; Audrey de Jong; Sandrine Valade; Michael Darmon; Agnès Veyradier; Elie Azoulay
Journal:  Intensive Care Med       Date:  2018-05-11       Impact factor: 17.440

Review 4.  Mechanisms of Coronary Ischemia in Women.

Authors:  Jingwen Huang; Sonali Kumar; Olga Toleva; Puja K Mehta
Journal:  Curr Cardiol Rep       Date:  2022-07-29       Impact factor: 3.955

5.  Prognostic value of dynamic cardiac biomarkers in patients with acquired refractory thrombocytopenic purpura: A retrospective study in Chinese population.

Authors:  Yinan Xu; Chengyuan Gu; Ruju Wang; Jiaqian Qi; Jun Wang; Tingbo Jiang; Min Jiang; Depei Wu; Tao You; Jianhong Fu
Journal:  J Clin Lab Anal       Date:  2022-06-11       Impact factor: 3.124

6.  Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Authors:  Elie Azoulay; Philippe R Bauer; Eric Mariotte; Lene Russell; Paul Knoebl; Ignacio Martin-Loeches; Frédéric Pène; Kathryn Puxty; Pedro Povoa; Andreas Barratt-Due; Jose Garnacho-Montero; Julia Wendon; Laveena Munshi; Dominique Benoit; Michael von Bergwelt-Baildon; Marco Maggiorini; Paul Coppo; Spero Cataland; Agnès Veyradier; Andry Van de Louw
Journal:  Intensive Care Med       Date:  2019-10-07       Impact factor: 17.440

Review 7.  Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease.

Authors:  Fedaey Abbas; Mohsen El Kossi; Jon Jin Kim; Ajay Sharma; Ahmed Halawa
Journal:  World J Transplant       Date:  2018-09-10

Review 8.  Severe Thrombotic Thrombocytopenic Purpura (TTP) with Organ Failure in Critically Ill Patients.

Authors:  Sofiane Fodil; Lara Zafrani
Journal:  J Clin Med       Date:  2022-02-19       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.